KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trial.

Jason V Baker, Lianne Siegel, Marcelo Losso, Shikha Vasudeva, Jacqueline A Nordwall, Katrina Harper, Birgit Grund, Joshua P Havens, Courtney V Fletcher, Roman Fishchuk, Olena Kobrynska, Akaki Abutidze, Revaz Metchurtchlishvili, Adit Ginde, Neil R Aggarwal, Garyphiallia Poulakou, Ahmad Mourad, Kevin Gibbs, Sho Saito, Methee Chayakulkeeree, Piroon Mootsikapun, Hitoshi Honda, Lourdes Mateu, Olga Gyrina, Angie Garcia, Dong-Gun Lee, Jonathan D Casey, Mamta K Jain, Charles D Bengtson, R Duncan Hite, Napon Hiranburana, Michael Matthay, Natalia Arizmendez, Hien H Nguyen, Alexander Drelick, Alfredo J Mena Lora, Sam Parnia, Barbara W Trautner, Simon D Portsmouth, Ryosuke Shimizu, Takeki Uehara, Roger Paredes, Anna Goodman, David M Vock, Annetine C Gelijns, Amy C Weintrob, Kristina L Bajema, Sarah L Pett, Jens Lundgren, Adam J Schechner, Elizabeth S Higgs, H Clifford Lane, Gail V Matthews, Wesley H Self, Cavan Reilly

Clin Infect Dis ciag272

PMID42017206
PMCID-
DOI10.1093/cid/ciag272
发表日期2026-04-22
摘要

摘要

BACKGROUND: Antivirals remain an important treatment strategy for persons who experience severe and life-threatening COVID-19. Ensitrelvir is an oral 3CL protease inhibitor with potent antiviral activity. METHODS: We conducted an international randomized, placebo-controlled trial of ensitrelvir with standard of care (SOC) among adults hospitalized for COVID-19. The primary outcome was clinical recovery assessed by the Days to Recovery Scale through Day 60 (DRS-60), analyzed using a Van Elteren test. RESULTS: From 2023 to 2025, 589 participants received blinded study treatment (293 ensitrelvir and 296 placebo). Median age was 69 years, 49% were female, 68% were White, and SOC commonly included corticosteroids (61% and 54%) and remdesivir (62% and 60%) in ensitrelvir and placebo groups, respectively. Median DRS-60 category was 6 (IQR: 3-15) in the ensitrelvir and 5.5 (IQR: 3-12) in the placebo group (p=0.19), and the OR was 0.82 (95% CI: 0.62-1.09) for a better DRS-60 category with ensitrelvir. Ensitrelvir participants had lower detectable viral antigen in plasma at Day 5 (13.4% vs 25.1%; p<0.001). There was no difference in secondary clinical outcomes or pre-specified safety outcomes, though the mortality rate was 6.1% vs 4.4% and the frequency of hemorrhagic events was 3.4% vs 0.3% among ensitrelvir and placebo groups, respectively. CONCLUSIONS: Ensitrelvir treatment did not improve clinical recovery in addition to SOC for adults hospitalized for COVID-19. The lower illness severity in the Omicron era compared to earlier periods in the COVID-19 pandemic, and high use of remdesivir and corticosteroids, may have contributed to the lack of clinical benefit.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。